Here are some examples of our Emerging Growth Reports. Below Each you will find a link to view the full report.
Natural Shrimp, Inc. (OTCQB: SHMP)
Natural Shrimp Inc. (OTCQB: SHMP) This agro-tech company has patented a new technology for growing Pacific White Shrimp in an indoor recirculation aquaculture system that doesn’t require the use of antibiotics.
The new technology is called ‘vibrio suppression technology.’ As the name suggests, this technology suppresses bacteria and viruses that afflict shrimp and lower yields in enclosed aquaculture systems, eliminating the need for costly and increasingly unpopular antibiotics.
Recently, some of the bigger players in the food and beverage market have been making forays into the seafood market through acquisitions. For example, in 2018, Tyson Foods Inc. (NYSE: TSN), the Arkansas food processing giant known mostly for chicken, acquired Keystone Foods from Brazil’s Marfrig Global Foods for $2.16 billion in cash.
A price target of 80% of the potential acquisition price—$1.0 per share—over the next 8-12 months would be a good exit point for a risk tolerant investor.
Click here for the full report
Galectin Therapeutics (NASDAQ: GALT)
This is going to be a candid article about how Galectin Therapeutics (NASDAQ: GALT) news announcements have not resonated with investors despite the enormity of news and implications to all future cancer research.
Have you ever heard of Pembrolizumab? You are not alone. Few investors have. Have you ever heard of Keytruda? Sure you have. Watch prime time television and you will see a commercial 3 times an hour. You associate it with curing the dreaded cancer – Melanoma. On Monday, November 12, 2017, Galectin Therapeutics told the investment community in the title of the press release that Pembrolizunab when paired with the Galectin-3 Inhibitor Gr-MD-O2 shows Promising Early Results In Treatment Of Advanced Melanoma from a Phase 1b Clinical Trial. The press release failed to resonate with anyone other than academicians. Investors didn’t know how to respond. What if GALT had simply replaced Pembrolizumab with Keytruda? What a difference! Then investors would fueling takeover speculation since GR-MD-02 seems to make Merck’s (NYSE: MRK) blockbuster drug Keytruda twice as good in 1/8th the time. Making this a must have acquisition target for any drug giant including MRK.
Click here for the full report
American Premium Water Corporation (OTC Pink: HIPH_
Cannabidiol, or CBD, is one of the fastest growing subsectors of the cannabis industry. Unlike THC, CBDs do not get you “high” yet it provides a wide range of health benefits. CBDs are legal in all 50 states and are not subject to the same strict regulations as THC. CBD-based products provide consumers a chance to benefit from the medicinal properties of cannabis without the impairment.
According to Statista, U.S. CBD consumer sales are expected to rise from $358.3 million in 2017 to $1.81 billion by 2022. Analysts believe that as more states legalize cannabis, CBD will continue to gain mainstream recognition.
One company that could be a major benefactor from the CBD boom is American Premium Water Corporation (OTC Pink: HIPH).
Click here for the full report
Ampio Pharmaceuticals (NASDAQ: AMPE)
Ampio Pharmaceuticals (NASDAQ: AMPE) keeps chugging away at the Biologics License Application (BLA) process and could be one FDA letter away from a major breakthrough that could pave the way toward a licensing or partnership deal. Numerous social media attacks have eroded the market cap to approximately $50 million from $300 million on August 7, 2018.
Unfortunately the company fueled the flames when they entered into a draconian financing for $7.5million in stock and warrants at $.40 in August right after announcing that there was a possibility that another trial might need to be done. The market has overreacted to this news sending it plummeting down almost 85% in 2 days. Another trial is no more than a 6 month delay, but the market has crushed the stock to below its phase 2 market capitalization when in fact they could get a letter back from the FDA at any time accepting AP-003-C as a pivotal trial. This letter or clinical trial with a Special Protocol Assessment (SPA) is all that stands between them in order for them to ink a partnership or outright sale of the company.
The market has over corrected to the point that it has derisked any chance of success in a clinical trial. What the market is missing is that they might not even need to do another clinical trial. Assuming they did need to complete an SPA it would be one of short duration, and statistically achievable.
Click here for the full report
nFusz, Inc. (OTCQB: FUSZ)
The digital advertising industry is forecast to see substantial growth over the next several years, thanks to continued growth in mobile computing and social media usage. According to Statista.com, the entire U.S. digital advertising market is forecast to see total revenue of $80.18 billion in 2016. By 2021, Statista analysts predict the U.S. digital advertising market will be pulling in $116.1 billion in total revenue.
Hollywood, California-based (Currently nFusz, Inc. (OTCQB: FUSZ) is an entertainment technology company. Through the company’s bNotifi technology, bBooth, Inc. (OTCQB: BBTH) is the first company able to deliver direct “push-to-screen,” interactive video messaging and advertising content to mobile and desktop screens world-wide. This technology is great for consumer brands looking for more effective ways to engage their customers, or for music artists seeking to interact with their fans and promote their latest tracks or upcoming concerts.
Click here for the full report
Puration, Inc. (OTC Pink: PURA)
The U.S. sports drinks market recorded sales of $6.33 billion for the 52 weeks ended February 25, 2018, according to data from Statista. PepsiCo’s(NASDAQ: PEP) flagship sports drink, Gatorade, and Coca-Cola’s(NYSE: KO), Powerade, currently dominate this market, with their brands commanding a cumulative market share of well over 95%.
Epidiolex is manufactured by GW Pharmaceuticals (NASDAQ: GWPH), which at the time of writing, was the most valuable medical marijuana company with a market cap of $4.27 billion. Epidiolex’s runaway success, as well as increased public interest in CBD, has put CBD on the radar of many health-conscious consumers in the U.S.
One small player in the CBD-infused sports drink market that is worth adding to your watchlist is Texas-based Puration Inc. (OTCPK: PURA). Its CBD-infused flagship beverage, EVERx, which acts as a pain reliever and also helps with muscle soreness, is gaining traction in the fitness market. For the nine months ending September 30, 2018, revenue from EVERx grew over 400% to $868,300, compared with $168,000 for the same period a year earlier. Moreover, the company realized a 50% profit margin, reporting a $448,800 bottom line for the nine months period under review.
Click here for the full report
